News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
698,859 Results
Type
Article (41552)
Company Profile (460)
Press Release (656847)
Section
Business (208461)
Career Advice (1999)
Deals (35942)
Drug Delivery (91)
Drug Development (83315)
Employer Resources (169)
FDA (16331)
Job Trends (15043)
News (352183)
Policy (32993)
Tag
Academia (2623)
Alliances (50590)
Alzheimer's disease (1257)
Approvals (16242)
Artificial intelligence (123)
Bankruptcy (361)
Best Places to Work (11661)
Biotechnology (345)
Breast cancer (105)
Cancer (917)
Career advice (1669)
Cell therapy (207)
Clinical research (65680)
Collaboration (336)
Compensation (159)
COVID-19 (2581)
Cystic fibrosis (82)
Data (848)
Diabetes (132)
Diagnostics (6149)
Drug pricing (83)
Earnings (85377)
Employer resources (147)
Events (112245)
Executive appointments (244)
FDA (16767)
Funding (300)
Gene therapy (161)
GLP-1 (589)
Government (4402)
Healthcare (18983)
Infectious disease (2654)
Inflammatory bowel disease (107)
Interviews (308)
IPO (16543)
Job creations (3694)
Job search strategy (1427)
Layoffs (434)
Legal (7923)
Lung cancer (158)
Manufacturing (152)
Medical device (13290)
Medtech (13295)
Mergers & acquisitions (19395)
Metabolic disorders (371)
Neuroscience (1508)
NextGen Class of 2024 (6731)
Non-profit (4532)
Northern California (1194)
Obesity (222)
Opinion (194)
Patents (95)
People (57475)
Pharmaceutical (86)
Phase I (20569)
Phase II (28978)
Phase III (21459)
Pipeline (205)
Postmarket research (2590)
Preclinical (8819)
Radiopharmaceuticals (250)
Rare diseases (192)
Real estate (5996)
Regulatory (21882)
Research institute (2405)
Resumes & cover letters (351)
Southern California (1083)
Startups (3746)
United States (11821)
Vaccines (550)
Weight loss (171)
Date
Last 7 days (795)
Last 30 days (2737)
Last 365 days (36627)
2024 (31055)
2023 (41015)
2022 (52287)
2021 (56775)
2020 (54933)
2019 (47434)
2018 (35710)
2017 (33035)
2016 (32364)
2015 (38423)
2014 (32199)
2013 (27128)
2012 (29240)
2011 (29876)
2010 (28018)
Location
Africa (734)
Arizona (194)
Asia (38417)
Australia (6397)
California (2756)
Canada (1170)
China (210)
Colorado (118)
Connecticut (126)
Europe (83755)
Florida (388)
Georgia (98)
Illinois (318)
Indiana (178)
Kansas (98)
Maryland (520)
Massachusetts (2279)
Michigan (144)
Minnesota (252)
New Jersey (821)
New York (840)
North Carolina (714)
Northern California (1194)
Ohio (124)
Pennsylvania (744)
South America (1107)
Southern California (1083)
Texas (386)
Washington State (329)
698,859 Results for "tg therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
TG Therapeutics, Inc. announced its financial results for the first quarter of 2024, along with recent company developments.
May 1, 2024
·
19 min read
Press Releases
TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update
November 1, 2024
·
1 min read
Business
TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update
TG Therapeutics, Inc., announced that a conference call will be held tomorrow, Wednesday, May 1, 2024, at 8:30 AM ET to discuss results for the first quarter of 2024 and provide a business outlook for 2024.
April 30, 2024
·
1 min read
Pharm Country
TG Therapeutics to Participate in the Jefferies Global Healthcare ConferenceFireside chat scheduled for Wednesday, June 5, 2024, at 1:30 PM ET
TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference, being held at the Marriott Marquis, in New York City on June 5-6, 2024.
June 3, 2024
·
1 min read
Pharm Country
TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI ® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting.
May 31, 2024
·
13 min read
Pharm Country
TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceFireside chat scheduled for Tuesday, June 11, 2024, at 1:20 PM ET
TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference, being held at the Loews Miami Beach Hotel, Miami Beach, FL on June 10-13, 2024.
June 7, 2024
·
1 min read
Business
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results
TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the fourth quarter and year ended December 31, 2023, along with recent company developments.
February 28, 2024
·
20 min read
Pharm Country
TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, being held May 29 – June 1, 2024, in Nashville, Tennessee.
May 28, 2024
·
14 min read
Business
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
TG Therapeutics, Inc. (NASDAQ: TGTX), announced that it has been awarded a national contract with the Department of Veterans Affairs (VA) for BRIUMVI® (ublituximab-xiiy) to be the preferred agent listed on the VA National Formulary for Anti-CD20 Antibody indications for patients with relapsing forms of multiple sclerosis (RMS).
April 18, 2024
·
13 min read
Pharm Country
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 American Academy of Neurology (AAN) annual meeting, being held in Denver, Colorado.
April 15, 2024
·
14 min read
1 of 69,886
Next
